Log In
Print
BCIQ
Print
Print this Print this
 

Crush-resistant Opana ER, oxymorphone

  Manage Alerts
Collapse Summary General Information
Company Endo International plc
DescriptionCrush-resistant formulation of an extended-release opioid analgesic formulated using Gruenenthal's INTAC technology
Molecular Target Mu opioid receptor (OPRM1) (MOR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPain
Indication DetailsTreat moderate to severe pain in patients requiring continuous opioid treatment
Regulatory Designation

Partner

Gruenenthal Group


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today